Professional
Added to YB: 2024-11-08
Pitch date: 2024-11-07
LLY [bullish]
Eli Lilly and Company
+29.05%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$796.23
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Show full summary:
Aristotle Large Cap Growth New Position: Eli Lilly and Company
LLY: Pharma leader w/ 50%+ US rev from Trulicity, Verzenio, Taltz. Deep pipeline in metabolic, oncology, immunology, CNS. Mounjaro potential beyond T2D & obesity. Orforglipron (oral GLP-1) & retatrutide (triple incretin) in P3. Premium valuation justified by growth outlook.
Read full article (1 min)